{
    "Trade/Device Name(s)": [
        "AggreGuide A-100 ADP Assay"
    ],
    "Submitter Information": "Aggredyne, Inc.",
    "510(k) Number": "K181777",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141427"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JOZ"
    ],
    "Summary Letter Date": "March 29, 2019",
    "Summary Letter Received Date": "July 3, 2018",
    "Submission Date": "June 29, 2018",
    "Regulation Number(s)": [
        "21 CFR 864.5700"
    ],
    "Regulation Name(s)": [
        "Automated platelet aggregation system"
    ],
    "Analyte Class(es)": [
        "hematology",
        "coagulation"
    ],
    "Analyte(s)": [
        "Platelet aggregation",
        "Adenosine diphosphate (ADP)"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "Sodium citrate tube (3.2%)"
    ],
    "Instrument(s)/Platform(s)": [
        "AggreGuide A-100 instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Laser light scattering",
        "Freeze dried agonist",
        "Disposable cartridge"
    ],
    "Methodologies": [
        "Platelet function testing",
        "Optical measurement of aggregation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Aggredyne AggreGuide A-100 ADP Assay for detecting platelet dysfunction using ADP-induced aggregation measured by light scattering",
    "Indications for Use Summary": "For detection of platelet dysfunction in patients aged 22 or older receiving P2Y12 antiplatelet drugs (prasugrel and ticagrelor) using sodium citrated whole blood, used with the AggreGuide A-100 instrument in non-CLIA waived physician\u2019s office or clinical laboratory",
    "fda_folder": "Hematology"
}